Depleting CD47 in GBM cells significantly increases macrophage phagocytosis and inhibits GBM tumor growth (87), indicating the therapeutic potential of targeting the CD47/SIRPα axis in GBM patients. This evidence concerns the gene SIRPA and glioblastoma.